Common TitleSofosbuvir for HCV Recurrence Following Liver Transplantation
Official Title Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection after Liver Transplantation
Phase Phase II
ClinicalTrials.gov NCT01687270
Treatments
Sofosbuvir

Sofosbuvir
Tradename:SovaldiOther Names:SOFClass:FDA-ApprovedCategories Resistance/Virological FailureTreatment-NaiveTreatment-Experienced
Funding
IndustryGilead Sciences
References
- Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108-17.